Novonesis AS Class B
NSIS B: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| DKK 876.00 | Rmq | Cbyvbscx |
Novonesis: A Biosolutions Powerhouse Is Born
Business Strategy and Outlook
Novonesis, created in 2024 through the merger of Novozymes and Chr. Hansen, is the global leader in the industrial enzymes and microbial solutions, or cultures, markets. Enzymes are biological catalysts that allow customers across many different industries to achieve greater yields, better performance, or lower costs for products and production processes, primarily by reducing raw material and energy requirements. Its microbial solutions portfolio caters to the food, beverage, agriculture, and human health end markets. Its products are essential for the fermentation process in dairy and for providing health benefits for dietary supplements and infant nutrition.